Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...
More than a decade after coining “Treat Yo’ Self Day” in her role as Donna on “Parks & Recreation,” Retta is once again ...
Zacks.com on MSN9h
TNDM Stock Likely to Gain From Innovation Amid CompetitionTandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...
No pain, no gain,” that’s what Trivariate Research highlighted about stocks that have exploded nearly 1,000% over 5-year ...
DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...
DexCom Inc (DXCM) stock saw a decline, ending the day at $68.94 which represents a decrease of $-1.15 or -1.64% from the prior close of $70.09. The stock opened at $69.99 and touched a low of $68.59 ...
Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...
These once-sizable artificial intelligence (AI) holdings for Google parent Alphabet have been paired down big-time over the ...
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) on September 13 and set a price target of ...
New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback